Ivan Bergstein

This inventor holds 20 USPTO granted patents and 20 published patent applications, plus 2 CIPO patents and 6 EPO patents. Top assignees: Stemline Therapeutics, Inc., Steamline Therapeutics, Inc., Other. Active years: 1999-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ivan Bergstein. Retrieved from https://idiyas.com/inventor/ivan-bergstein

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 (Patent Applications = 20)

% Patents Active = 70.0

CIPO Patents = 2 (Patent Applications = 5)

EPO Patents = 6 (Patent Applications = 13)

Average Co-Inventor Count = 1.1

ph-index = 6

Forward Citations = 227(Granted Patents)

Company Filing History:

11 out of 11

Stemline Therapeutics, Inc.

patents

1 out of 1

Steamline Therapeutics, Inc.

patent

8 out of 834,513

Other

patents

Years Active: 1999-2026

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12678485 - Methods of Treating an Autoimmune Disease with a Human Interleukin-3 (IL-3)-Diphtheria Toxin Conjugate (DT-IL3) (2026-07-14),

2. 12357700 - Combination therapy method of treating myeloproliferative neoplasms with a diphtheria toxin-human interleukin-3 conjugate in combination with other agents (2025-07-15),

3. 12357678 - Cancer stem cell targeted cancer vaccines (2025-07-15),

4. 12187802 - IL3Ralpha antibodies and uses thereof (2025-01-07),

5. 11672847 - Cancer stem cell targeted cancer vaccines (2023-06-13),

6. 10906979 - IL3Ralpha antibody conjugates and uses thereof (2021-02-02),

7. 10485858 - Cancer stem cell targeted cancer vaccines (2019-11-26),

8. 10316098 - IL3Rα antibody conjugates and uses thereof (2019-06-11),

9. 9873743 - IL3Rα antibody conjugates and uses thereof (2018-01-23),

10. 9518119 - IL3Rα antibody conjugates and uses thereof (2016-12-13),

11. 8992910 - IL3Rα antibody conjugates and uses thereof (2015-03-31),

12. 8846325 - Methods of cancer diagnosis and therapy targeted against a cancer stem line (2014-09-30),

13. 8715945 - Methods of cancer diagnosis and therapy targeted against a cancer stem line (2014-05-06),

14. 8163279 - IL3Rα antibody conjugates and uses thereof (2012-04-24),

15. 8038998 - Methods of cancer therapy targeted against a cancer stemline (2011-10-18),

Title: Ivan Bergstein: Innovator in Cancer Treatment

Introduction

Ivan Bergstein is a noteworthy inventor based in New York, NY, with a remarkable portfolio consisting of 19 patents. His work primarily focuses on innovative therapies for cancer treatment, significantly impacting the medical field.

Latest Patents

Among his latest inventions, Bergstein has developed a combination therapy method for treating myeloproliferative neoplasms, utilizing a diphtheria toxin-human interleukin-3 conjugate in conjunction with other agents. This invention aims to enhance treatment efficacy for patients suffering from these types of cancers. Furthermore, he has also created cancer stem cell targeted cancer vaccines, providing comprehensive methods for treating and vaccinating against cancer. These vaccines include detailed regimens that combine various immunomodulatory agents and peptides, tailored to specific patient populations.

Career Highlights

Throughout his career, Ivan Bergstein has played a pivotal role in advancing cancer research and treatment methodologies. His contributions have established him as a leading figure in the field of oncology, leveraging his expertise to develop groundbreaking therapies that address unmet medical needs.

Collaborations

Bergstein has collaborated with esteemed colleagues, including Thomas P. Cirrito and Christopher Brooks. These partnerships have fostered an environment of innovation, enabling the development of effective treatment options for cancer patients.

Conclusion

Ivan Bergstein continues to be an influential inventor whose work has the potential to transform cancer treatment. With numerous patents to his name and a dedication to advancing medical science, his contributions are highly regarded within the scientific community.

Profile summary based on public USPTO records.